Avadel Pharmaceuticals

Developing a once-nightly treatment for patients with narcolepsy

Avadel is primarily focused on the development and FDA approval of FT218, an investigational, once-nightly, extended-release formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in adults with narcolepsy. FT218 has been granted Orphan Drug Designation from the U.S. FDA for the treatment of narcolepsy.

Status
NASDAQ: AVDL
Year of Investment
2021
Strategy
Life Sciences
Location
Ireland